InFocus Capital Partners

Visibly is a healthcare technology company based in Chicago that provides online eye examinations and digital vision care services. It offers remote refractive assessments to determine prescriptions for glasses or contact lenses and supports optical businesses with online vision testing, prescription renewals, and integrated digital tools. The company serves consumers, eye care providers, insurers, online health platforms, and optical retailers through e-commerce channels, enabling convenient access to vision care and streamlined operations for practitioners. Formerly Opternative, it rebranded as Visibly in 2018 and was founded in 2013.

Re-Vana Therapeutics specializes in ocular pharmaceuticals and drug delivery systems. It develops biodegradable platforms to treat chronic eye diseases like age-related macular degeneration, diabetic retinopathy, glaucoma, and retina infections. Key products include OcuLief for AMD and DR treatment, and EyeLief for glaucoma and retina disease management.

Stuart Therapeutics is a biotechnology company focused on developing innovative therapies for ophthalmic conditions. The company's primary offering, PolyCol, is a synthesized peptide therapeutic platform designed to repair disease-damaged helical collagen in the eye. This platform facilitates accelerated healing of epithelial cells, restoration of nerve function, and reduction of inflammation, making it a promising treatment for various ophthalmic diseases, including dry eye disease, dry age-related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, supplemented by additional intellectual property acquired by the company. Beyond ophthalmic applications, Stuart Therapeutics is also exploring PolyCol's potential in treating gastrointestinal, inflammatory, and oncology conditions.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Re-Vana Therapeutics specializes in ocular pharmaceuticals and drug delivery systems. It develops biodegradable platforms to treat chronic eye diseases like age-related macular degeneration, diabetic retinopathy, glaucoma, and retina infections. Key products include OcuLief for AMD and DR treatment, and EyeLief for glaucoma and retina disease management.

Founded in 2015, Mojo Vision specializes in developing and commercializing advanced micro-LED display technology for various applications. The company is renowned for creating the world's smallest dynamic display for augmented reality smart contact lenses. Headquartered in Saratoga, California, Mojo Vision aims to disrupt the $160 billion display industry with its proprietary quantum-dot technology.

ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Pr3vent, Inc. is a technology company based in Palo Alto, California, that specializes in artificial intelligence and machine learning applications for screening ophthalmic conditions in newborns. Established in 2017, Pr3vent focuses on providing affordable and effective eye exams for infants, utilizing a wide-angle fundus camera to capture comprehensive images of the retina. Their advanced algorithms analyze these images to detect abnormalities and generate referral recommendations when necessary. By enabling timely examination and treatment, Pr3vent's innovative approach aims to prevent vision loss in babies, ensuring that potential issues are identified and addressed as early as possible.

IACTA Pharmaceuticals is a company focused on developing innovative eyecare products aimed at treating diseases and enhancing patient outcomes. The firm specializes in a hydrophobic drug designed for encapsulation and delivery to ocular tissues, which facilitates improved permeation and effectiveness in addressing conditions such as dry eye. IACTA Pharmaceuticals emphasizes the importance of collaboration among business partners, scientists, and patients, recognizing that successful pharmaceutical development extends beyond mere scientific advancement to include the insights and needs of the people involved.

Founded in 2015, Qura develops ultra-miniature implantable devices for monitoring physiological pressure changes. These devices have the potential to transform biomedicine by enabling real-time disease monitoring and timely treatments.

Alievio, Inc. is a North Carolina-based company that specializes in the design, development, and manufacturing of innovative ophthalmic medical devices for glaucoma patients. The company has introduced a novel device, Sollevio, which offers a noninvasive method for titrating postoperative intraocular pressure in the treatment of refractory glaucoma. This device serves as a significant advancement in glaucoma therapy, aiming to address the complications associated with traditional glaucoma surgeries while providing ophthalmologists with a valuable tool to halt the progression of the disease. Founded in 2010 and originally known as Camras Vision, Inc., Alievio changed its name in June 2019 and operates from Research Triangle Park, North Carolina.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.